Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM

from Oncology Learning Network · host HMP Global

Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Episode metadata supplied by the publisher feed · Published Dec 15, 2021

Embed this episode

Attribution link and audio player

Ready to play

Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM

0:00 6:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 6 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on December 15, 2021.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!